JP2004526725A - フッ化トリエンおよびｒｘｒモジュレータとしてのその使用 - Google Patents

フッ化トリエンおよびｒｘｒモジュレータとしてのその使用 Download PDF

Info

Publication number
JP2004526725A
JP2004526725A JP2002571445A JP2002571445A JP2004526725A JP 2004526725 A JP2004526725 A JP 2004526725A JP 2002571445 A JP2002571445 A JP 2002571445A JP 2002571445 A JP2002571445 A JP 2002571445A JP 2004526725 A JP2004526725 A JP 2004526725A
Authority
JP
Japan
Prior art keywords
optionally substituted
alkyl
aryl
methyl
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002571445A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004526725A5 (cg-RX-API-DMAC10.html
Inventor
ベル，マイケル，グレゴリー
グレーセ，ティモシー，アラン
ガーナート，ダグ，リン
ユミベ，ネイサン，ピー．
ボーム，マーカス，エフ．
ミシェリス，ピエール−イブ
アーデッキー，ロバート，ジェイ．
マペス，クリストファー，エム．
チェン，ジュン−フン
タイホナス，ジョン，エス．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of JP2004526725A publication Critical patent/JP2004526725A/ja
Publication of JP2004526725A5 publication Critical patent/JP2004526725A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
JP2002571445A 2001-03-14 2002-03-12 フッ化トリエンおよびｒｘｒモジュレータとしてのその使用 Pending JP2004526725A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27580801P 2001-03-14 2001-03-14
PCT/US2002/007718 WO2002072528A1 (en) 2001-03-14 2002-03-12 Fluorinated trienes and their use as rxr modulators

Publications (2)

Publication Number Publication Date
JP2004526725A true JP2004526725A (ja) 2004-09-02
JP2004526725A5 JP2004526725A5 (cg-RX-API-DMAC10.html) 2005-12-22

Family

ID=23053886

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002571445A Pending JP2004526725A (ja) 2001-03-14 2002-03-12 フッ化トリエンおよびｒｘｒモジュレータとしてのその使用

Country Status (7)

Country Link
US (1) US20040248919A1 (cg-RX-API-DMAC10.html)
EP (1) EP1368296A1 (cg-RX-API-DMAC10.html)
JP (1) JP2004526725A (cg-RX-API-DMAC10.html)
AU (1) AU2002255732B2 (cg-RX-API-DMAC10.html)
CA (1) CA2438874A1 (cg-RX-API-DMAC10.html)
MX (1) MXPA03008229A (cg-RX-API-DMAC10.html)
WO (1) WO2002072528A1 (cg-RX-API-DMAC10.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010539168A (ja) * 2007-09-12 2010-12-16 ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク 黄斑変性症を処置するための組成物及び方法
JP2016149358A (ja) * 2015-02-10 2016-08-18 公益財団法人相模中央化学研究所 二次電池用電解液

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0785273A1 (en) 1990-11-26 1997-07-23 Genetics Institute, Inc. Paired basic amino acid converting enzyme and DNA sequence encoding it
CA2452541A1 (en) * 2001-07-20 2003-01-30 Eli Lilly And Company (pyridinyl and pyrimidyl) trienoic acid derivatives as retinoid x receptor modulators
GB0308335D0 (en) 2003-04-10 2003-05-14 Novartis Ag Organic compounds
US6887896B1 (en) * 2003-10-29 2005-05-03 Allergan, Inc. 7-[(7-Alkoxy)-chrom-3-en-6-yl]-heptatrienoic acid and 7-[(3-alkoxy)-5,6-dihydronaphthalen-2-yl]-heptatrienoic acid derivatives having serum glucose reducing activity
EP2428516A1 (en) 2003-11-19 2012-03-14 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
US20090232879A1 (en) 2005-05-26 2009-09-17 Metabasis Therapeutics, Inc. Thyromimetics for the Treatment of Fatty Liver Diseases
WO2018094265A2 (en) 2016-11-21 2018-05-24 Viking Therapeutics, Inc. Method of treating glycogen storage disease
AU2018280118B2 (en) 2017-06-05 2021-07-15 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
EA202091979A1 (ru) 2018-03-22 2021-06-22 Вайкинг Терапьютикс, Инк. Кристаллические формы и способы получения кристаллических форм соединения
EP4775207A2 (en) 2018-12-05 2026-07-15 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
EP4161925A4 (en) 2020-06-09 2024-09-04 Viking Therapeutics, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISEASES

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071773A (en) * 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
US4981784A (en) * 1987-12-02 1991-01-01 The Salk Institute For Biological Studies Retinoic acid receptor method
US5977125A (en) * 1994-10-31 1999-11-02 Eisai Co., Ltd. Mono-or polyenic carboxylic acid derivatives
EP0788353A1 (en) * 1995-09-18 1997-08-13 Ligand Pharmaceuticals, Inc. Ppar gamma antagonists for treating obesity
AU726450B2 (en) * 1995-10-06 2000-11-09 Ligand Pharmaceuticals Incorporated Dimer-selective RXR modulators and methods for their use
WO2000026172A1 (en) * 1998-11-03 2000-05-11 Ligand Pharmaceuticals Incorporated Trienoic retinoid compounds as retinoic acid receptor antagonists
CN1337931A (zh) * 1999-03-08 2002-02-27 巴斯利尔药物股份公司 类维生素a拮抗剂及其用途
US6593493B1 (en) * 1999-09-14 2003-07-15 Ligand Pharmaceuticals, Inc. RXR modulators with improved pharmacologic profile
CA2452541A1 (en) * 2001-07-20 2003-01-30 Eli Lilly And Company (pyridinyl and pyrimidyl) trienoic acid derivatives as retinoid x receptor modulators

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010539168A (ja) * 2007-09-12 2010-12-16 ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク 黄斑変性症を処置するための組成物及び方法
US8877809B2 (en) 2007-09-12 2014-11-04 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating macular degeneration
US9486432B2 (en) 2007-09-12 2016-11-08 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating macular degeneration
USRE47045E1 (en) 2007-09-12 2018-09-18 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating macular degeneration
JP2016149358A (ja) * 2015-02-10 2016-08-18 公益財団法人相模中央化学研究所 二次電池用電解液

Also Published As

Publication number Publication date
AU2002255732B2 (en) 2006-03-09
EP1368296A1 (en) 2003-12-10
US20040248919A1 (en) 2004-12-09
WO2002072528A1 (en) 2002-09-19
CA2438874A1 (en) 2002-09-19
MXPA03008229A (es) 2004-11-12

Similar Documents

Publication Publication Date Title
KR100625255B1 (ko) 다이머-선택적rxr변조물질및그의사용방법
US6083977A (en) Trienoic retinoid compounds and methods
US6593493B1 (en) RXR modulators with improved pharmacologic profile
EP0800503B1 (en) Novel trienoic retinoid compounds and methods
JP2004532194A (ja) レチノイドｘレセプターモジュレータ
AU2002255732B2 (en) Fluorinated trienes and their use as RXR modulators
AU2002255732A1 (en) Fluorinated trienes and their use as RXR modulators
US7019034B2 (en) Compositions and methods for reducing serum glucose and triglyceride levels in diabetic mammals
US6005007A (en) Retinoids, methods for their production and use
EP0800504B1 (en) Tricyclic retinoids, methods for their production and use
WO2004069781A2 (en) 7-(3,5-diisopropylphenyl) heptatrienoic acid derivatives having serum glucose reducing activity
JP2005514327A (ja) レチノイドｘレセプターモジュレータとしての（ピリジニルおよびピミジル）トリエン酸誘導体
AU2002319583A1 (en) (Pyridinyl and pyrimidyl) trienoic acid derivatives as retinoid X receptor modulators
JP2002511053A (ja) レチノイド型四環芳香族化合物の製造方法及び利用
KR20060079254A (ko) 다이머-선택적 ｒｘｒ 변조물질 및 그의 사용방법
WO2000026173A1 (en) Novel retinoids, methods for their production and use
EP0879223A1 (fr) Derives polycycliques aromatiques de type retinoide, leur procede de preparation et leur utilisation pour la fabrication de compositions pharmaceutiques et cosmetiques
US20040198825A1 (en) 5,6,7,8-Tetrahydronaphthalen-2-yl-7-fluoroalkyl-heptatrienoic acid derivatives having serum glucose reducing activity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050303

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20050404

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080822

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20080827

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090220